APO Research
Talk to an analyst

APO RESEARCH · REPORT

Small Molecule Multi-target Angiogenesis Inhibitor

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032

27 December 2025100 pages

Choose your research edition.

Industry ResearchSmall Molecule Multi-target Angiogenesis Inhibitor Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Small Molecule Multi-target Angiogenesis Inhibitor Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Small Molecule Multi-target Angiogenesis Inhibitor Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Small Molecule Multi-target Angiogenesis Inhibitor market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Small Molecule Multi-target Angiogenesis Inhibitor is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Small Molecule Multi-target Angiogenesis Inhibitor include Chia Tai Tianqing, Teva, Jiangsu Hengrui Pharmaceuticals, TWi Pharmaceuticals, Sanofi, Pfizer, Novartis, Janssen Biotech and Exelixis, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Small Molecule Multi-target Angiogenesis Inhibitor market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Small Molecule Multi-target Angiogenesis Inhibitor market size, estimates, and forecasts are presented in terms of sales volume (K Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Small Molecule Multi-target Angiogenesis Inhibitor market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Small Molecule Multi-target Angiogenesis Inhibitor.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Small Molecule Multi-target Angiogenesis Inhibitor market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Small Molecule Multi-target Angiogenesis Inhibitor Market by Company

Chia Tai Tianqing

Teva

Jiangsu Hengrui Pharmaceuticals

TWi Pharmaceuticals

Sanofi

Pfizer

Novartis

Janssen Biotech

Exelixis

Eisai

Boehringer Ingelheim

Bayer

AstraZeneca.

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Type

Apatinib

Axitinib

Anlotinib

Vandetanib

Cabozantinib

Lenvatinib

Pazopanib

Sunitinib

Sorafenib

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Application

Cancer Therapy

Inflammatory and Autoimmune Diseases

Ophthalmic Diseases

Other

Small Molecule Multi-target Angiogenesis Inhibitor Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Small Molecule Multi-target Angiogenesis Inhibitor market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Small Molecule Multi-target Angiogenesis Inhibitor and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Small Molecule Multi-target Angiogenesis Inhibitor.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Small Molecule Multi-target Angiogenesis Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Small Molecule Multi-target Angiogenesis Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Apatinib Table 2. Major Company of Axitinib Table 3. Major Company of Anlotinib Table 4. Major Company of Vandetanib Table 5. Major Company of Cabozantinib Table 6. Major Company of Lenvatinib Table 7. Major Company of Pazopanib Table 8. Major Company of Sunitinib Table 9. Major Company of Sorafenib Table 10. Major Company of Other Table 11. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 12. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 13. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type (2021-2026) Table 14. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 15. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type (2021-2026) Table 16. Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Type (2021-2026) & (US$/Unit) Table 17. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2027-2032) & (K Units) Table 18. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type (2027-2032) Table 19. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2027-2032) & (US$ Million) Table 20. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type (2027-2032) Table 21. Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Type (2027-2032) & (US$/Unit) Table 22. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 23. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 24. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 25. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 26. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 27. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 28. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 29. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 30. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (K Units) Table 31. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Type (2021-2026) & (US$ Million) Table 32. Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends Table 33. Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers Table 34. Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges Table 35. Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints Table 36. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Revenue by Company (US$ Million) & (2021-2026) Table 37. Global Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Company (2021-2026) Table 38. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Company (2021-2026) & (K Units) Table 39. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Company (2021-2026) Table 40. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Price by Company (2021-2026) & (US$/Unit) Table 41. Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026 Table 42. Global Small Molecule Multi-target Angiogenesis Inhibitor Major Company Production Sites and Headquarters Table 43. Global Small Molecule Multi-target Angiogenesis Inhibitor Company, Product Type & Application Table 44. Global Small Molecule Multi-target Angiogenesis Inhibitor Company Establishment Date Table 45. Global Company Market Concentration Ratio (CR5 and HHI) Table 46. Global Small Molecule Multi-target Angiogenesis Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 47. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 48. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (K Units) Table 49. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Region (2021-2026) Table 50. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2021-2026) & (US$ Million) Table 51. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Region (2021-2026) Table 52. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 53. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2027-2032) & (K Units) Table 54. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Region (2027-2032) Table 55. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Region (2027-2032) & (US$ Million) Table 56. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Region (2027-2032) Table 57. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 58. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 59. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 60. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application (2021-2026) Table 61. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 62. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application (2021-2026) Table 63. Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Application (2021-2026) & (US$/Unit) Table 64. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2027-2032) & (K Units) Table 65. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application (2027-2032) Table 66. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2027-2032) & (US$ Million) Table 67. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application (2027-2032) Table 68. Global Small Molecule Multi-target Angiogenesis Inhibitor Price by Application (2027-2032) & (US$/Unit) Table 69. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 70. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 71. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 72. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 73. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 74. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 75. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 76. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 77. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (K Units) Table 78. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Application (2021-2026) & (US$ Million) Table 79. Chia Tai Tianqing Company Information Table 80. Chia Tai Tianqing Business Overview Table 81. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 83. Chia Tai Tianqing Recent Development Table 84. Teva Company Information Table 85. Teva Business Overview Table 86. Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 88. Teva Recent Development Table 89. Jiangsu Hengrui Pharmaceuticals Company Information Table 90. Jiangsu Hengrui Pharmaceuticals Business Overview Table 91. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 93. Jiangsu Hengrui Pharmaceuticals Recent Development Table 94. TWi Pharmaceuticals Company Information Table 95. TWi Pharmaceuticals Business Overview Table 96. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 98. TWi Pharmaceuticals Recent Development Table 99. Sanofi Company Information Table 100. Sanofi Business Overview Table 101. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 103. Sanofi Recent Development Table 104. Pfizer Company Information Table 105. Pfizer Business Overview Table 106. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 108. Pfizer Recent Development Table 109. Novartis Company Information Table 110. Novartis Business Overview Table 111. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 113. Novartis Recent Development Table 114. Janssen Biotech Company Information Table 115. Janssen Biotech Business Overview Table 116. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 118. Janssen Biotech Recent Development Table 119. Exelixis Company Information Table 120. Exelixis Business Overview Table 121. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 123. Exelixis Recent Development Table 124. Eisai Company Information Table 125. Eisai Business Overview Table 126. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 128. Eisai Recent Development Table 129. Boehringer Ingelheim Company Information Table 130. Boehringer Ingelheim Business Overview Table 131. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 133. Boehringer Ingelheim Recent Development Table 134. Bayer Company Information Table 135. Bayer Business Overview Table 136. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 138. Bayer Recent Development Table 139. AstraZeneca. Company Information Table 140. AstraZeneca. Business Overview Table 141. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio Table 143. AstraZeneca. Recent Development Table 144. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 145. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 146. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 147. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 148. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 149. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 150. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 151. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country (2021-2026) Table 152. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 153. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Share Forecast by Country (2027-2032) Table 154. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 155. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 156. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 157. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 158. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 159. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 160. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 161. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country (2021-2026) Table 162. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 163. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Share Forecast by Country (2027-2032) Table 164. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 165. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 166. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 167. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 168. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 169. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 170. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 171. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country (2021-2026) Table 172. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 173. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Share Forecast by Country (2027-2032) Table 174. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 175. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 176. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 177. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 178. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 179. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 180. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 181. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country (2021-2026) Table 182. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 183. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Share Forecast by Country (2027-2032) Table 184. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (K Units): 2021 VS 2025 VS 2032 Table 185. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026) & (K Units) Table 186. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share by Country (2021-2026) Table 187. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032) & (K Units) Table 188. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share Forecast by Country (2027-2032) Table 189. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 190. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026) & (US$ Million) Table 191. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country (2021-2026) Table 192. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032) & (US$ Million) Table 193. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Share Forecast by Country (2027-2032) Table 194. Key Raw Materials Table 195. Raw Materials Key Suppliers Table 196. Small Molecule Multi-target Angiogenesis Inhibitor Distributors List Table 197. Small Molecule Multi-target Angiogenesis Inhibitor Customers List Table 198. Research Programs/Design for This Report Table 199. Authors List of This Report Table 200. Secondary Sources Table 201. Primary Sources List of Figures Figure 1. Small Molecule Multi-target Angiogenesis Inhibitor Image Figure 2. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size (2021-2032) & (US$ Million) Figure 4. Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (2021-2032) & (K Units) Figure 5. Apatinib Image Figure 6. Global Apatinib Sales YoY Growth (2021-2032) & (K Units) Figure 7. Axitinib Image Figure 8. Global Axitinib Sales YoY Growth (2021-2032) & (K Units) Figure 9. Anlotinib Image Figure 10. Global Anlotinib Sales YoY Growth (2021-2032) & (K Units) Figure 11. Vandetanib Image Figure 12. Global Vandetanib Sales YoY Growth (2021-2032) & (K Units) Figure 13. Cabozantinib Image Figure 14. Global Cabozantinib Sales YoY Growth (2021-2032) & (K Units) Figure 15. Lenvatinib Image Figure 16. Global Lenvatinib Sales YoY Growth (2021-2032) & (K Units) Figure 17. Pazopanib Image Figure 18. Global Pazopanib Sales YoY Growth (2021-2032) & (K Units) Figure 19. Sunitinib Image Figure 20. Global Sunitinib Sales YoY Growth (2021-2032) & (K Units) Figure 21. Sorafenib Image Figure 22. Global Sorafenib Sales YoY Growth (2021-2032) & (K Units) Figure 23. Other Image Figure 24. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 25. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Overview by Type (2021-2032) & (US$ Million) Figure 26. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Type 2025 VS 2032 Figure 27. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type in 2025 Figure 28. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type in 2025 Figure 29. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type in 2025 Figure 30. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type in 2025 Figure 31. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type in 2025 Figure 32. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type in 2025 Figure 33. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type in 2025 Figure 34. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type in 2025 Figure 35. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Type in 2025 Figure 36. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Type in 2025 Figure 37. Global Top 5 and 10 Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025 Figure 38. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 39. Cancer Therapy Image Figure 40. Global Cancer Therapy Sales YoY Growth (2021-2032) & (K Units) Figure 41. Inflammatory and Autoimmune Diseases Image Figure 42. Global Inflammatory and Autoimmune Diseases Sales YoY Growth (2021-2032) & (K Units) Figure 43. Ophthalmic Diseases Image Figure 44. Global Ophthalmic Diseases Sales YoY Growth (2021-2032) & (K Units) Figure 45. Other Image Figure 46. Global Other Sales YoY Growth (2021-2032) & (K Units) Figure 47. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Overview by Application (2021-2032) & (US$ Million) Figure 48. Global Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Application 2025 VS 2032 Figure 49. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application in 2025 Figure 50. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application in 2025 Figure 51. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application in 2025 Figure 52. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application in 2025 Figure 53. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application in 2025 Figure 54. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application in 2025 Figure 55. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application in 2025 Figure 56. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application in 2025 Figure 57. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Volume by Application in 2025 Figure 58. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Market Share in Value by Application in 2025 Figure 59. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 60. North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. North America Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 64. Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 68. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 69. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 70. Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 71. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 72. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 73. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 74. Latin America Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 75. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country: 2021 VS 2025 VS 2032 (K Units) Figure 76. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Share by Country: 2021 VS 2025 VS 2032 Figure 77. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 78. Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Share by Country: 2021 VS 2025 VS 2032 Figure 79. Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Figure 80. Key Raw Materials Price Figure 81. Manufacturing Cost Structure Figure 82. Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process Figure 83. Direct Comparison with Distribution Share Figure 84. Distributors Profiles Figure 85. Years Considered Figure 86. Research Process Figure 87. Key Executives Interviewed

Scope & coverage.

Types
  • Apatinib
  • Axitinib
  • Anlotinib
  • Vandetanib
  • Cabozantinib
  • Lenvatinib
  • Pazopanib
  • Sunitinib
  • Sorafenib
  • Other
Applications
  • Cancer Therapy
  • Inflammatory and Autoimmune Diseases
  • Ophthalmic Diseases
  • Other
Companies covered
  • Chia Tai Tianqing
  • Teva
  • Jiangsu Hengrui Pharmaceuticals
  • TWi Pharmaceuticals
  • Sanofi
  • Pfizer
  • Novartis
  • Janssen Biotech
  • Exelixis
  • Eisai
  • Boehringer Ingelheim
  • Bayer
  • AstraZeneca.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Small Molecule Multi-target Angiogenesis Inhibitor Market by Type
  6. 1.3.1 Apatinib
  7. 1.3.2 Axitinib
  8. 1.3.3 Anlotinib
  9. 1.3.4 Vandetanib
  10. 1.3.5 Cabozantinib
  11. 1.3.6 Lenvatinib
  12. 1.3.7 Pazopanib
  13. 1.3.8 Sunitinib
  14. 1.3.9 Sorafenib
  15. 1.3.10 Other
  16. 1.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Type
  17. 1.4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Overview by Type (2021-2032)
  18. 1.4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Historic Market Size Review by Type (2021-2026)
  19. 1.4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecasted Market Size by Type (2027-2032)
  20. 1.5 Key Regions Market Size by Type
  21. 1.5.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Type (2021-2026)
  22. 1.5.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Type (2021-2026)
  23. 1.5.3 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Type (2021-2026)
  24. 1.5.4 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Type (2021-2026)
  25. 1.5.5 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Small Molecule Multi-target Angiogenesis Inhibitor Industry Trends
  2. 2.2 Small Molecule Multi-target Angiogenesis Inhibitor Industry Drivers
  3. 2.3 Small Molecule Multi-target Angiogenesis Inhibitor Industry Opportunities and Challenges
  4. 2.4 Small Molecule Multi-target Angiogenesis Inhibitor Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Small Molecule Multi-target Angiogenesis Inhibitor Revenue (2021-2026)
  2. 3.2 Global Top Players by Small Molecule Multi-target Angiogenesis Inhibitor Sales (2021-2026)
  3. 3.3 Global Top Players by Small Molecule Multi-target Angiogenesis Inhibitor Price (2021-2026)
  4. 3.4 Global Small Molecule Multi-target Angiogenesis Inhibitor Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Small Molecule Multi-target Angiogenesis Inhibitor Major Company Production Sites & Headquarters
  6. 3.6 Global Small Molecule Multi-target Angiogenesis Inhibitor Company, Product Type & Application
  7. 3.7 Global Small Molecule Multi-target Angiogenesis Inhibitor Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Small Molecule Multi-target Angiogenesis Inhibitor Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Small Molecule Multi-target Angiogenesis Inhibitor Tier 1, Tier 2, and Tier 3
4 Small Molecule Multi-target Angiogenesis Inhibitor Regional Status and Outlook
  1. 4.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Historic Market Size by Region
  3. 4.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecasted Market Size by Region
  7. 4.3.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Small Molecule Multi-target Angiogenesis Inhibitor by Application
  1. 5.1 Small Molecule Multi-target Angiogenesis Inhibitor Market by Application
  2. 5.1.1 Cancer Therapy
  3. 5.1.2 Inflammatory and Autoimmune Diseases
  4. 5.1.3 Ophthalmic Diseases
  5. 5.1.4 Other
  6. 5.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Application
  7. 5.2.1 Global Small Molecule Multi-target Angiogenesis Inhibitor Market Size Overview by Application (2021-2032)
  8. 5.2.2 Global Small Molecule Multi-target Angiogenesis Inhibitor Historic Market Size Review by Application (2021-2026)
  9. 5.2.3 Global Small Molecule Multi-target Angiogenesis Inhibitor Forecasted Market Size by Application (2027-2032)
  10. 5.3 Key Regions Market Size by Application
  11. 5.3.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Application (2021-2026)
  12. 5.3.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Application (2021-2026)
  13. 5.3.3 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Application (2021-2026)
  14. 5.3.4 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Application (2021-2026)
  15. 5.3.5 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai Tianqing
  2. 6.1.1 Chia Tai Tianqing Company Information
  3. 6.1.2 Chia Tai Tianqing Business Overview
  4. 6.1.3 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai Tianqing Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  6. 6.1.5 Chia Tai Tianqing Recent Developments
  7. 6.2 Teva
  8. 6.2.1 Teva Company Information
  9. 6.2.2 Teva Business Overview
  10. 6.2.3 Teva Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Teva Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  12. 6.2.5 Teva Recent Developments
  13. 6.3 Jiangsu Hengrui Pharmaceuticals
  14. 6.3.1 Jiangsu Hengrui Pharmaceuticals Company Information
  15. 6.3.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  16. 6.3.3 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Jiangsu Hengrui Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  18. 6.3.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  19. 6.4 TWi Pharmaceuticals
  20. 6.4.1 TWi Pharmaceuticals Company Information
  21. 6.4.2 TWi Pharmaceuticals Business Overview
  22. 6.4.3 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 TWi Pharmaceuticals Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  24. 6.4.5 TWi Pharmaceuticals Recent Developments
  25. 6.5 Sanofi
  26. 6.5.1 Sanofi Company Information
  27. 6.5.2 Sanofi Business Overview
  28. 6.5.3 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Sanofi Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  30. 6.5.5 Sanofi Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Novartis
  38. 6.7.1 Novartis Company Information
  39. 6.7.2 Novartis Business Overview
  40. 6.7.3 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Novartis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  42. 6.7.5 Novartis Recent Developments
  43. 6.8 Janssen Biotech
  44. 6.8.1 Janssen Biotech Company Information
  45. 6.8.2 Janssen Biotech Business Overview
  46. 6.8.3 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Janssen Biotech Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  48. 6.8.5 Janssen Biotech Recent Developments
  49. 6.9 Exelixis
  50. 6.9.1 Exelixis Company Information
  51. 6.9.2 Exelixis Business Overview
  52. 6.9.3 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Exelixis Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  54. 6.9.5 Exelixis Recent Developments
  55. 6.10 Eisai
  56. 6.10.1 Eisai Company Information
  57. 6.10.2 Eisai Business Overview
  58. 6.10.3 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Eisai Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  60. 6.10.5 Eisai Recent Developments
  61. 6.11 Boehringer Ingelheim
  62. 6.11.1 Boehringer Ingelheim Company Information
  63. 6.11.2 Boehringer Ingelheim Business Overview
  64. 6.11.3 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Boehringer Ingelheim Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  66. 6.11.5 Boehringer Ingelheim Recent Developments
  67. 6.12 Bayer
  68. 6.12.1 Bayer Company Information
  69. 6.12.2 Bayer Business Overview
  70. 6.12.3 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Bayer Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  72. 6.12.5 Bayer Recent Developments
  73. 6.13 AstraZeneca.
  74. 6.13.1 AstraZeneca. Company Information
  75. 6.13.2 AstraZeneca. Business Overview
  76. 6.13.3 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 AstraZeneca. Small Molecule Multi-target Angiogenesis Inhibitor Product Portfolio
  78. 6.13.5 AstraZeneca. Recent Developments
7 North America by Country
  1. 7.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country
  2. 7.1.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  4. 7.1.3 North America Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032)
  5. 7.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country
  6. 7.2.1 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026)
  8. 7.2.3 North America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country
  2. 8.1.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  4. 8.1.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country
  6. 8.2.1 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026)
  8. 8.2.3 Europe Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country
  2. 9.1.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country
  6. 9.2.1 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country
  2. 10.1.1 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  4. 10.1.3 South America Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032)
  5. 10.2 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country
  6. 10.2.1 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026)
  8. 10.2.3 South America Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country
  2. 11.1.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country
  6. 11.2.1 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Small Molecule Multi-target Angiogenesis Inhibitor Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Small Molecule Multi-target Angiogenesis Inhibitor Value Chain Analysis
  2. 12.1.1 Small Molecule Multi-target Angiogenesis Inhibitor Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Small Molecule Multi-target Angiogenesis Inhibitor Production Mode & Process
  7. 12.2 Small Molecule Multi-target Angiogenesis Inhibitor Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Small Molecule Multi-target Angiogenesis Inhibitor Distributors
  10. 12.2.3 Small Molecule Multi-target Angiogenesis Inhibitor Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst